ProBiotix Health Plc (‘ProBiotix’), a life sciences company developing probiotics to support cardiometabolic health, has strengthened its global footprint with a new partnership agreement with supplement specialist DanCare for the distribution of its InstaMelt product in China.
This strategic move marks a significant step for ProBiotix Health in penetrating the Chinese health and nutrition market with cardiometabolic supplement solutions. The InstaMelt formulation, ProBiotix’s newly developed food supplement, offers innovative features for health brands and retailers, and will be fully rebranded as a finished turn-key solution by DanCare.
InstaMelt is a direct dose stick solution that melts instantly on the tongue and contains ProBiotix’s proprietary IP protected probiotic strain LPLDL®, shown through comprehensive human studies to improve multiple cardiometabolic health biomarkers including decreasing harmful LDL cholesterol and increasing HDL cholesterol levels.
Steen Andersen, CEO of ProBiotix, commented: “This partnership with DanCare, a well-recognised high-quality innovative brand in China, positions us to address the growing consumer focus on cardiometabolic health in the region. With reports showing that cardiovascular disease is on the rise and an estimated 155 million Chinese adults having elevated cholesterol levels, our collaboration with DanCare enables us to effectively engage with this market, and support health and nutrition brands across China.
“InstaMelt is a fantastic solution for brand owners in the Chinese market, demonstrating how ProBiotix is putting a key focus not only on scientific evidence, but also on innovative, convenient and consumer-led delivery methods. Our approach meets the evolving needs of consumers while maintaining the highest standards of efficacy.”
DanCare, founded in 2003, has evolved from supplying branded products to the European supplement industry to becoming a global supplement and functional ingredient organisation with a strong presence in China. The company offers a broad range of clinically documented, high-quality supplements marketed globally under the DanCare brand.
The CEO and spokesperson of DanCare China commented: “We are looking forward to this collaboration with ProBiotix Health as our two companies share the same vision of improving quality of life by bringing efficacious, high quality innovate supplements to market. The significant clinical documentation backing the strain LPLDL®, in combination with the innovative new stick dosage format and DanCare’s strong market position, will be an excellent addition to our product line in the Chinese market. This sets high growth expectations for the product. We are excited to see where this dynamic partnership leads.”
Set to launch under the DanCare brand in Q4 2024, InstaMelt is available in fresh fruity flavours, designed to be taken once daily after a main meal. Aligning with the diversity of today’s global health consumer market, it is vegan, allergen-free and GMO-free.
This partnership agreement represents a key milestone in ProBiotix’s drive to expand its reach and bring its innovative cardiometabolic health solutions to the global market to support longer and healthier lives.